Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33478
Title: A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD.
Austin Authors: Kanaan, Richard A A ;Oliver, Gina;Dharan, Anita ;Sendi, Shahbaz;Maier, Alice ;Mohebbi, Mohammadreza;Ng, Chee;Back, Sudie E;Kalivas, Peter;Berk, Michael
Affiliation: Psychiatry (University of Melbourne)
University of Melbourne, Department of Psychiatry, The Melbourne Clinic, Richmond, VIC, Australia.
School of Medicine, Barwon Health, Deakin University, IMPACT - The Institute for Mental and Physical Health and Clinical Translation, Geelong, Australia; Deakin University, Faculty of Health, Biostatistics Unit, Geelong, Australia.
University of Melbourne, Department of Psychiatry, The Melbourne Clinic, Richmond, VIC, Australia.
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Department of Neuroscience, Medical University of South Carolina, USA; Ralph H Johnson VA Medical Center, Charleston, SC, USA.
School of Medicine, Barwon Health, Deakin University, IMPACT - The Institute for Mental and Physical Health and Clinical Translation, Geelong, Australia; Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia.
Issue Date: 30-Jul-2023
Date: 2023
Publication information: Psychiatry Research 2023-07-30; 327
Abstract: PTSD may involve oxidative stress, and N-acetylcysteine (NAC) may reduce the impact of oxidative stress in the brain. This study aims to investigate the efficacy of adjuvant NAC in people with treatment-resistant PTSD. A multicentre, randomised, double-blind, placebo-controlled trial for adults with PTSD unresponsive to first-line treatment. The intervention was either oral NAC 2.7 g/day or placebo for 12 weeks. The primary outcome was change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at 12 weeks compared with baseline. Secondary outcomes included depression and substance craving. Follow-up measures were obtained at 16 and 64-weeks. 133 patients were assessed, with 105 randomised; 81 participants completed the 12-week trial, 79 completed week-16 follow-up, and 21 completed week-64 follow-up. There were no significant differences between those taking NAC and those taking placebo in CAPS-5 scores at week 12, nor in secondary outcomes. Significant between-group differences were observed at week 64 in craving duration (Cohen's d = 1.61) and craving resistance (Cohen's d = 1.03), both in favour of NAC. This was the first multicentre, double-blind, randomised, placebo-controlled trial of adjunctive NAC for treatment-resistant PTSD. No benefit of NAC was observed in this group beyond that provided by placebo at end of the trial. ACTRN12618001784202, retrospectively registered 31/10/2018, URL: http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376004.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33478
DOI: 10.1016/j.psychres.2023.115398
ORCID: 
Journal: Psychiatry Research
Start page: 115398
PubMed URL: 37540942
ISSN: 1872-7123
Type: Journal Article
Subjects: N-acetyl cysteine
Oxidative stress
Post-traumatic stress disorder
Randomised controlled trial
Treatment
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on Mar 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.